
TOMA Biosciences: A genomics firm offering physicians data-driven cancer treatment optimization.
TOMA Biosciences, founded with a mission to revolutionize cancer treatment, leverages advanced genomics to provide physicians with critical data for optimizing patient care. The company’s core vision is to transform next-generation sequencing (NGS) technology into a powerful tool for detecting clinically significant changes in tumor DNA. TOMA's proprietary sequencing solutions enable laboratories to uncover DNA alterations in cancer cells, providing actionable insights for personalized treatment strategies.
Notable affiliates and investors in TOMA Biosciences include leading figures and institutions in the genomics and biotech sectors. The company has achieved significant milestones, including the development of its cutting-edge sequencing technology and successful partnerships with medical laboratories. TOMA's impact lies in its ability to enhance the precision of cancer treatments, thereby improving patient outcomes and advancing the field of personalized medicine.

Tome Biosciences
tome.bio

Genomenon
genomenon.com

TMA Precision Health

Data Driven Bioscience

Sequegenics
sequegenics.com

Foundation Medicine

GenomOncology
genomoncology.com

Genome Insight

NantOmics
nantomics.com

BioDatomics
biodatomics.com

Bioinfoexperts
bioinfox.com

Sentieon
sentieon.com

Ultima Genomics
ultimagenomics.com

Personal Genome Diagnostics
personalgenome.com

GenomeNext
Companies similar to Toma Biosciences include Tome Biosciences, Genomenon, TMA Precision Health and Data Driven Bioscience.
Toma Biosciences was founded in 2011.
Toma Biosciences' headquarters is located in Foster City, CA, US.
Toma Biosciences' most recent funding round was for $7.8k (USD) in February 2019.
As of Feb 1, 2019, Toma Biosciences has raised a total of $14.7M (USD).
Toma Biosciences has 11 employees as of Feb 5, 2024.